HG202 represents a novel approach to treating neovascular age-related macular degeneration (nAMD) by utilizing high-fidelity CRISPR/Cas13 technology for RNA editing. This therapy aims to reduce the burden of frequent anti-VEGF injections, which are the current standard of care but have limitations including suboptimal responses in 25-35% of patients and associated risks of complications. The potential for a one-time treatment with long-term effects could position HG202 favorably in a market dominated by anti-VEGF therapies, which are projected to grow significantly due to the increasing prevalence of AMD. The successful development and commercialization of HG202 may disrupt the current treatment paradigm and provide a competitive edge for HuidaGene Therapeutics, especially if it demonstrates superior efficacy and safety profiles in clinical trials.